Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Optibiotix Health lines up the targets for its “Precision microbiome engineering”

OptiBiotix has been a pioneer of the human microbiome, which is essentially the bacteria that inhabits the gut and skin.
cartoon of cholesterol
Optibiotix can target HDL, the good cholesterol

Stephen O’Hara, Optibiotix Health PLC's (LON:OPTI) chief executive, believes his company will have ‘many shots on goal’ in the coming years as it develops its range of products based around the human microbiome.

The company has scored once already with the recent float of SkinBioTherapeutics PLC (LON:STBX), a company that has grown in value from around £400,000 to £11mln and an AIM listing in little more than a year.

Now the plan is to repeat the formula with the group’s three other divisions.

Microbiome pioneer

OptiBiotix has been a pioneer of the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food and that had led to a range of products being developed by the company that are now approaching the commercial stage.

O’Hara says it can use bacteria to build complex sugars that act like fibres, which allows it change the microbiome in a very targeted way.

“Precision microbiome engineering” is what O’Hara calls it and it’s a phrase he says the market is going to be hearing much more of in future.

Separate listings 

O’Hara sees potential for each of its weight loss, pro-biotics and sugars operations, and indeed Skinbiotherapeutics where it still has a 42% stake, to match Optibiotix’s current market value. 

The process of separating the three divisions along the lines of SkinBiotherapeutics has already started with Optibiotix also beefing up the commercial capability of each.

Eventually that may see further separate listings or even a Nasdaq listing for the whole group.

“We were a science company, now we are a commercial company with proven technologies and proven products in the market place.”

Products now the focus

Industry leaders Tata Chemical, pro-biotics specialist Sacco and Bened in Asia have all recently agreed deals for a variety of Optibiotix’s products.

Tata’s deal was for appetite suppressant Slimbiome. A  new version of the flour-like weight loss additive will be launched in the US at Las Vegas this week while a backlog of orders has built up from the earlier VitaFoods exhibition in Europe.

The upgrade makes its easier to mix, easier to dissolve and ensures better flavours opening up markets such as gym users who want a shake and bakeries that can fold it in for bread.

O'Hara says he had one order before the product had even gone on show at Vitafoods

Risk strategy pays off

When starting Optibiotix he knew working on the microbiome would be really exciting but to spread the risk, because it was so new, went for a number of different options.

“In three years in a new area of science, the microbiome, we’ve developed across four areas, developed 60 patents, twenty trademarks and are now starting to launch products.”

“We thought one or two might fail, but all have worked."

At 65.2p, Optibiotix is valued at £51.4mln.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use